Patient and HCP attitudes and behaviours towards insulin therapy in Australia (GAPP2), and latest news on Novo Nordisk injectable therapies
An international cross-sectional survey (GAPP2), with a cohort in Australia, was conducted to increase the understanding of basal insulin-taking with an aim to investigate the frequency and impact of basal insulin dosing irregularities and hypoglycaemia in type 2 diabetes. The survey was conducted with both patients and physicians, and thus the difference in perceptions between the two groups was explored. The survey found a proportion of patients dosed their basal insulin irregularly which may warrant more frequent discussion with prescribers to address the behaviours and reasons behind this.
Novo Nordisk is constantly exploring opportunities to make their products more widely available to a larger number of patient groups. An update to the audience will be provided on the latest developments of Novo Nordisk’s injectable portfolio.
Diabetes, high risk sub-groups and the implications of hypoglycaemia
This session will increase awareness of diabetes high risk sub-groups, such as the elderly and those with renal impairment. The implications of hyperglycaemia and hypoglycaemia within these groups will be discussed and management options will be reviewed. As a result of attending this session attendees will enhance their skills in avoiding hypoglycaemia whilst still achieving good glycaemic control.
Confirmed speakers are:
Dr Ted Wu - Senior Staff Specialist in Endocrinology and Diabetes, Director of Health Professional Training, Royal Prince Alfred, Camperdown, NSW
Associate Professor Marg McGill AM - Manager, Diabetes Centre, Royal Prince Alfred Hospital, Camperdown, NSW
Addressing the preventable toll of chronic disease and premature death among people with a serious mental illness
Kevin Humphries is the NSW Minister for Mental Health, Minister for Healthy Lifestyles and Minister for Western NSW.The Minister will discuss work being undertaken at a national level, commenced by a recent national summit formed to discuss the physical health of people with a mental illness and the high rates of chronic and preventable disease.
The summit was held in response to increasing concerns within the community and also growing evidence which shows that one in five Australians experience a mental health difficulty in any given year and the physical health of people living with a mental health difficulty is worse than those in the general community on just about every measure. Of particular focus is that people with a severe mental illness live between 10-32 years less than the general population. People with illnesses such as bipolar disorder or schizophrenia have heart-related problems, diabetes and obesity at much higher rates than the rest of the community.
An overview of dapagliflozin (FORXIGA®): clinical trials and in-clinic experience
Dapagliflozin (Forxiga) is a sodium glucose co-transporter inhibitor (SGLT2i), a new class of oral type 2 diabetes medication which inhibits renal glucose reabsorption resulting in urinary glucose excretion . The action of dapagliflozin is independent of insulin and does not impair normal endogenous glucose production in response to hypoglycaemia1. In addition to improving glycaemic control, the urinary glucose excretion induced by dapagliflozin is associated with reduction in weight but also contributes to its adverse effect profile which includes genital infections, urinary tract infections and volume depletion1. Dapagliflozin was the first SGLT2i to be approved for use in the management of type 2 diabetes1. It has been registered in Australia as well as in Europe. The objective of this symposium is to provide attendees with a balanced overview of the dapagliflozin clinical trials program and to share the early in-clinic experience with dapagliflozin in Europe.
Modifying the Natural History of Type 1 Diabetes Across the Life Spectrum
GP CME Eligible Session
An exploration of e-health and available technology and its applicability in diabetes self management in the 21st century.
GP CME Eligible Session
Delegates involved in the poster discussion are required to stand by their poster on Thursday 29th August from 2:00 PM – 2:30 PM. Presentations will be in 5 minute slots – 3 minutes to summarise research and 2 minutes to answer any questions.
Complications Chairperson - Elif I Ekinci
Diabetic Foot Chairperson - Pete Lazzarini
Type 1/Young DM Chairperson - Maria Craig
Glycaemia/Validity Chairperson - Gregory Fulcher
Trials Chairperson - Neale Cohen
Treatment/Prevention Chairperson - Stephen Stranks
GP CME Eligible Session
The two societies bring out their best for an hour of skillful debating that will challenge your current ideas and move you to consider different points of view.
Moderator: Timothy Davis
Affirmative: Trisha O’Moore-Sullivan and Cheryl Steel
Negative: Wah Cheung and Glynis Dent
Only ADS Members are able to attend the Annual General Meeting